bios - canadian healthcare marketing hall of fame 2013

7/22/2019 Bios - Canadian Healthcare Marketing Hall of Fame 2013

1/12

CanadianHealthcareMarketing Hall of Fame

Temple de la renomme canadien du

Marketing des Soins de Sant

Hall of Fame supplement 2013_rar6.qxd 4/8/2013 9:49 AM Page 1


2/12

Readers of The Chronicle of

Healthcare Marketinglast

year placed several dozen

names in nomination for consideration

for entry as

members of The CanadianHealthcare Marketing Hall of Fame.

The awards were

established to honour healthcare

marketers who have contributed to

our avocation and are an

inspiration to others.

These honourees were chosen from

this field of deserving candidates,

but stand for, in the view of the

selection committee, a

representative cross-section of the

qualities that make our business

unique and fulfilling. On behalf of

our readers, we extend to each

honouree our warm congratulations.

This years induction ceremony was

held on April 10, 2013 at the

Mississauga Convention Centre in

Mississauga, Ont. Host for the event

was Lorne Markowitz.

Please visit the Hall of Fame on the

World Wide Web at

www.chronicle.ca/halloffame/

Les lecteurs de la revue

Chronicle of Healthcare

Marketingont soumis

lan dernier des douzaines de

nominations en vue de la

slection des membres

du Temple de la renommecanadien du marketing des soins de

sant. Des prix seront ainsi dcernsaux spcialistes en marketing de soins

de sant qui ont grandement

contribu notre cause et se sont

rvls une source

dinspiration pour autrui.

Les personnes honores ont t

choisies parmi cet ventail de

candidats mritoires, mais

personnifient surtout, aux yeux du

comit de slection, un chantillon

reprsentatif des qualits qui dfinis-

sent le caractre unique et motivant

de notre secteur dactivit. Au nom de

tous nos lecteurs, nous tenons

exprimer chacun et

chacune de ces membres nos

flicitations les plus cordiales.

Cette anne, la crmonie

dintronisation a eu lieu le 10 Avril

2013 au Mississauga Convention

Centre Mississauga, en Ontario.

Lvnement tait anim par

M. Lorne Markowitz.

Veuillez rendre visite au Temple de la

renomme, sur le World Wide Web,

www.chronicle.ca/halloffame/



3/12

TO GLENN BLOCK, succeeding in business and contribut-ing to society were goals that are totally compatible. Ichose a business degree because it gave me a lot ofoptions, says Block, General Manager, Merz Pharma

Canada Ltd., who majored in marketing and earned aBachelor of Commerce from Queens University in

Kingston, Ont. I wanted to pursue a career in the world that wouldallow me to make a contribution and marry that with my passion forbusiness.

Block began his pharma career in 1991 in the sales force forAllergan Inc., focusing on ophthalmology therapeutics. One of theophthalmology products was Botox, which was originally used totreat strabismus and blepharospasm. Block was named SalesRepresentative of the Year in 1994 and in 1996 while in the field.

Botox was originally indicated for medical use, and it wasresearch by Vancouver physicians Alastair and Jean Carruthers thathighlighted to Allergan that the p roduct could offer more than strict-ly medical benefits.

The marketing lesson was to listen to our customer, saysBlock. The idea of where and how to best utilize a drug treatmentand determine what is a business opportunity can come from physi-

cians, since they have first-hand knowledge, working with patients.Block took a deeper dive in dermatology when he becameDirector, Dermatology Business Unit at Biogen Idec Canada in 2003.He credits his team with trail blazing and overcoming many hurdles in the launch of the bio-logic psoriasis therapy Amevive. We had a great team and a very successful Canadianlaunch. After success with dermatology, he took the position of Director, Neurology BusinessUnit, at the company. He increased sales of Avonex and prepared for the Canadian launch ofTysabri, both multiple sclerosis treatments.

In 2006, Block was approached by Merz and asked to evaluate the potential for the entryof a new botulinum toxin, Xeomin, into the Canadian marketplace. The challenge would beintroducing a competitor to Allergans long-established product. Block worked at Merzs headoffice in Frankfurt, Germany for a year before setting up the companys Canadian operationsin Burlington, Ont. more than four years ago.

The key to any organization is building a strong product portfolio and assembling a greatteam and I am extremely proud of the team we have put together, he says.

In the four years since the inception of Merz Pharma Canada, Block and his team nowhave products in the Neuroscience, Aesthetic Dermatology and the OTC spaces.

POUR GLENN BLOCK, russir en affaires et contribuer lasocit taient des objectifs entirement compatibles. Jai choisi dobtenir un diplme en commerce parceque cela mouvrait beaucoup de portes , affirme M.

Block, directeur gnral de Merz Pharma Canada Ltd.,spcialis en marketing et dtenteur dun baccalaurat en

commerce de la Queens University Kingston, en Ontario. Je voulaispoursuivre en ce monde une carrire qui me permettrait dapporter unecontribution et de marier cela avec ma passion pour les affaires.

M. Block a commenc sa carrire dans le secteur pharmaceutiqueen 1991, titre de reprsentant pour Allergan Inc., avec une spcialisation

en traitements ophtalmologiques. Lun des produits ophtalmologiquestait Botox, qui tait initialement utilis pour le traitement du strabismeet du blpharospasme. M. Block a t nomm reprsentant de lanne en1994 et en 1996, alors quil travaillait dans le domaine.

lorigine, Botox tait indiqu pour une utilisation mdicale, et cestla recherche effectue par Alastair et Jean Carruthers, deux mdecins deVancouver, qui a fait prendre conscience Allergan que le produit pourraitavoir des bienfaits qui ntaient pas exclusivement mdicaux.

La leon de marketing tait la suivante : il faut couter son client ,affirme M. Block. Ce sont les mdecins qui peuvent avoir lide concer-nant la meilleure faon dutiliser un traitement pharmaceutique et de

dterminer o se trouve une occasion daffaires, car ils ont des connais-sances de premire main dcoulant de leur travail avec les patients. M. Block sest impliqu encore plus profondment dans la derma-

tologie lorsquil est devenu directeur de lunit fonctionnelle de dermatologie chez Biogen Idec Canada,en 2003. Il exprime sa reconnaissance son quipe pour avoir franchi de nombreux obstacles au lance-

ment du traitement biologique du psoriasis Amevive. Nous avions une quipe formidable et avonsconnu un lancement canadien trs russi. Aprs avoir russi dans le secteur dermatologique, il aaccept le poste de directeur de lunit fonctionnelle de neurologie de la socit. Il a augment les ventes

dAvonex et a effectu les prparatifs en vue du lancement canadien de Tysabri, ces deux produitstant des traitements pour la sclrose en plaques.

En 2006, Merz apris contact avec M. Block et lui a demand dvaluer le potentiel de larrivedune nouvelle toxine botulinique, Xeomin, sur le march canadien. Le dfi consistait introduire un

concurrent au produit dAllergan, qui tait tabli de longue date. Pendant un an, M. Block a travaill ausige social de Merz, situ Francfort, en Allemagne, avant dinstaller les activits canadiennes de lasocit Burlington, en Ontario, il y a plus de quatre ans de cela.

La cl de toute organisation est de crer un solide portefeuille de produits et de monter une

grande quipe; et je suis extrmement fier de celle que nous avons mise en place. Au cours des qua-tre annes coules depuis la cration de Merz Pharma Canada, Glenn et son quipe ont maintenant des

produits relatifs la science neurologique, la dermatologie esthtique et les espaces grands public.

Glenn BlockMerz Pharma Canada

Burlington, Ont.

Canadian Healthcare Marketing Hall of Fame

Temple de la renomme canadien du marketing des soins de sant



4/12

MIKE EGLIS CAREERin the pharmaceutical industryhas spanned 30 years, and the President andChief Executive Officer of Takeda Canada Inc.continues to enjoy his career choice. A graduate

in economics from the University of Guelph inGuelph, Ont., Egli was approached by a neigh-

bour about a pharmaceutical sales opportunity. He went for an inter-view at Schering Canada and began working as a sales representativefor the company in the summer of 1983.

At Schering for nine years, Mike was involved with the launch ofClaritin and held a number of positions including Product Managerfor Claritin, Group Product Manager, and Regional Sales Manager(Atlantic Canada).

Every two years, I was challenged with another position,recalls Egli.

Egli joined Roche Canada in the early 1990s and oversaw themarketing of the firms hospital products. He was also a key player inthe integration of Genentechs portfolio into Roche. In 1997, he washired as Director of Sales and Marketing at Byk Canada Inc. and wastasked with building the firm from scratch.

We had to build up the sales force, hire a complete marketing

department, and get a research team in place, says Egli, who co-leadthe co-promotion of the proton pump inhibitor Pantoloc (pantopro-zole) with Solvay Pharma Inc. Working with another company on aco-promotion was a l earning experience.

In 2004, Egli was promoted to General Manager, Altana Netherlands, and moved his fam-ily overseas. Working in Europe, you are dealing with different cultures, a different pharma-ceutical market, and you get more exposure to the head office and markets in other countriesthat are nearby, notes Egli.

Eglis plan was to be based in the Netherlands for three to four years, but that was extend-ed to seven years when Nycomed purchased Altana and a smooth integration was another chal-lenge facing Egli.

When Nycomed was acquired by Takeda in 2011, Egli seized the opportunity to return toCanada to head Takeda Canada Inc. The current objective is to build awareness of the Takedabrand.

The goal is to put Takeda on the map in Canada, says Egli. It is the number one [phar-maceutical] company in Japan. We have a very strong pipeline, and our aim is to successfullycommercialize the assets that we have in Canada. We are launching products every year overthe next few years.

Some of the therapeutic areas that are a focus for Takeda Canada include gastroenterol-ogy, respirology, oncology, and diabetes, notes Egli.

In his spare time, Egli, a resident of Oakville, Ont., plays hockey in the winter months andenjoys golfing in the summer months.

Egli says one secret to his success in the pharma industry has been to surround himselfwith talented people.

BASEBALL, BASKETBALL OU HOCKEY, il suffit quil y ait du sport

Mike EgliTakeda Canada Inc.

Oakville, Ont.





5/12

JOANNE KLUE, Marketing Services Director at CegedimRelationship Management in Scarborough, Ont., has adaptedto many changes in her career at the company, a career thathas now spanned nearly three decades and seen several

changes in corporate names and management. Klue joinedthe firm in 1985 when it was called Walsh as an account

manager, back when customer relationship management (CRM)solutions were paper-based. Since that time, the firm has been knownas IMS Health Strategic Technologies, Synavant, Dendrite, CegedimDendrite and now Cegedim, the only global solutions provider of bothsales and marketing products and services solutions for the life sci-ences sector.

Klue was instrumental in establishing a marketing services divi-sion within the company and has held various sales and managementpositions at the organization. She has been responsible for all directmarketing applications and custom communications, publisher cir-culation development and list supply, marketing target lists, print andfull-service letter shop services, as well as Physician Connect, thecompanys Key Opinion Leader mapping and identification system.

Over time, Klue has witnessed the dwindling of field forcesacross the pharma industry and has seen marketing efforts transformfrom huge endeavours to reach mass numbers of physicians to small-er projects focusing on marketing specialty products that are of inter-est to a specific group of physicians.

I think one of the big changes is that the days of clients mar-keting blockbuster drugs are gone, says Klue. Its more about reaching specialty audiencesto market niche products. We work directly with the pharma company or advertising agency tocreate a customized program where we will recommend multiple waves [of marketing con-tent] that are highly personalized.

Targeting smaller numbers of physicians creates an opportunity for relationship market-ing, according to Klue. We try to encourage communication between the client and the audi-ence more than we ever have before, she says.

And even in a digital age, Klue says a mix of media is optimal for effective marketing tohealthcare professionals. There will always be room for different approaches to marketing,says Klue. Marketing has to be multi-faceted to be successful. Print is still valuable, and is oneof the best ways of communicating information.

Relationship management demands staying current to the needs of the marketer and theacceptance level of the target market, adds Klue.

She can attest to the axiom that the more things change, the more they stay the same. As

things have changed in the industry, we have to sometimes work in a very different way withour clients, but it is about going back to basics and applying marketing principles, she says.

Klue, who recently stepped down after a decade of sitting on the Board of Directors of theOntario Pharmaceutical Marketing Association, has been actively involved in professionaldevelopment.

CE SONT LES ENJEUX STRATGIQUES plutt que lacommercialisation en tant que telle qui mat-tiraient, raconte Richard Fajzel, directeurgnral, Unit d'oncologie, Pfizer Canada. Jemintressais surtout la stratgie globale delentreprise, ainsi quau rle important jou

par la commercialisation cet gard. M. Fajzel a dmarr sa carrire chez Sandoz Montral, ville o il

a obtenu un baccalaurat s arts de lUniversit McGill et une matrise enadministration des affaires de lUniversit Concordia. Il a commenc partravailler dans la recherche sur les marchs, puis sest joint la force devente de lentreprise avant de devenir directeur de marque pour des pro-duits tels que lantifongique Lamisil et Parlodel, un traitement contrela maladie de Parkinson.

Aprs quatre ans en tant

Joanne KlueCegedim Relationship

Management

Scarborough, Ont.





6/12

AN A HEALTHCARE PRVETERAN and Co-Founder and ManagingPartner of energi PR, Digital, Communications, CarolLevine has been involved in the development of award-winning public relations programs. After graduating

from Montreals McGill University, Levine worked in thenon-profit and consumer sectors and currently applies

her expertise to successfully delivering innovative healthcare PR pro-grams to a client list that has included companies such as AstellasPharma Canada, Abbott, Biovail, Bristol-Myers Squibb, Galderma,Paladin Laboratories, Triton, and Merck, to name a few.

An entrepreneur at heart, Levine set up a PR consultancy in the1980s and later partnered with Esther Buchsbaum. The duo createda successful and national PR firm operating as CommunicationsMECA. After merging with another PR shop to form energi PR, withoffices in Toronto and Montreal, they bought out their partner lessthan two years ago.

Some notable accomplishments in Levines career have beenthe launch of Zostrix, a therapy designed to treat post-herpetic neu-ralgia, the Canadian launch of Protopic, a non-steroidal medicationfor eczema, as well as the launch and promotion of the biologicalagents Raptiva (efalizumab) and Amevive (alefacept), both inno-

vative treatments for psoriasis.Levines firm has been involved in the development of numer-ous patient education programs in dermatology and urology, focusingon conditions such as rosacea and eczema and overactive bladder. One patient education proj-ect she developed is a pre-transplant program aimed at preparing renal transplant recipientsfor the transplant process. Today, the program is available in numerous transplant centres inCanada and is compulsory in some.

The role of the PR professional is to be the clients trusted advisor, according to Levine,immediate Past Chair of the Canadian Council of Public Relations Firms and Chair of theBusiness Committee of the Public Relations Global Network. Ultimately, youre being paid toprovide your expertise, says Levine. Sometimes, that means disagreeing with a client but,done in a productive and positive way, it helps everyone get to the best answer for the busi-ness.

A new challenge in healthcare PR is managing the opportunities and impact of socialmedia. Even if a client isnt ready to take the plunge, they are counselled to understand socialmedia platforms like LinkedIn, Facebook and Twitter, as well as to monitor whats being saidabout their brands online, notes Levine.

Levine and her firm are also involved in patient advocacy and work with clients to help

bring the patients voice forward in a meaningful and impactful way, says Levine.A lot of very forward-thinking pharmaceutical companies have been building brands

with public relations, says Levine. She is honoured to be inducted into the CanadianHealthcare Marketing Hall of Fame, viewing this acknowledgement as recognition of PR withinthe healthcare marketing industry.

EN TANT QUE SPCIALISTE CHEVRONNE des relations publiquesdans le domaine de la sant et cofondatrice et associedirectrice de energi PR, numrique et communications,Carol Levine a t implique dans le dveloppement de

programmes de relations publiques prims. Aprs avoirobtenu son diplme de lUniversit McGill de Montral,

Mme Levine a travaill dans les secteurs sans but lucratif et des consom-mateurs et elle tire profit actuellement de son expertise pour offrir avecsuccs des programmes de relations publiques en soins de sant innova-teurs pour une liste de clients qui comprend des socits telles que AstellasPharma Canada, Abbott, Biovail, Bristol-Myers Squibb, Galderma, PaladinLaboratoires, Triton, et Merck, pour nen nommer que quelques-uns.

Entrepreneure dans lme, Mme Levine a mis en p lace un bureau-conseil en relations publiques dans les annes 1980, et plus tard en

partenariat avec Esther Buchsbaum. Le tandem a cr une entreprisenationale oprant avec succs sous le nom de Communications MECA.Aprs la fusion avec une autre socit en relations publiques pour formerenergi PR, elles ont rachet les parts de leur partenaire il y a moins de

deux ans. energi PR a ouvert des bureaux Toronto et Montreal.Quelques ralisations remarquables dans la carrire de Mme Levine

ont t le lancement de Zostrix, un traitement conu pour traiter lesnvralgies post-herptiques, le lancement canadien de Protopic, un

mdicament non strodal pour leczma, ainsi que le lancement et la

promotion des agents biologiques Raptiva (efalizumab) et Amevive

(alefacept), les deux traitements innovants pour le psoriasis.La firme de Mme Levine a t implique dans le dveloppement de nombreux programmes dd-

ucation des patients en dermatologie et en urologie, en se concentrant sur des maladies telles que larosace, leczma et lhyperactivit vsicale. Un projet dducation des patients quelle a dvelopp taitun programme de pr-transplantation visant prparer les bnficiaires de transplantations rnales pourle processus de transplantation. De nos jours, le programme est disponible dans de nombreux centres

de transplantation au Canada et est obligatoire dans certains pays.Le rle du professionnel en relations publiques est dtre le conseiller de confiance du client, selon

Mme Levine, prsidente sortante du Public Relations Firms (Conseil canadien des compagnies de rela-tions publiques), et prsidente du Business Committee of the Public Relations Global Network (Comit

des affaires du rseau global des relations publiques). Au bout du compte, vous tes pay pour fournirvotre expertise, dclare Mme Levine. Cela signifie parfois tre en dsaccord avec un client, mais celase fait dune manire positive et productive. Cela permet chacun dobtenir la meilleure rponse pourlentreprise.

Un nouveau dfi dans relations publiques lies aux soins de sant est de grer les opportunits etlimpact des mdias sociaux. Mme si un client nest pas prt franchir le pas, on leur conseille de com-prendre les plateformes des mdias sociaux tels que LinkedIn, Facebook et Twitter, ainsi que de surveillerce qui se dit en ligne sur leurs marques, fait remarquer Mme Levine.

Mme Levine et sa firme sont galement impliques dans la dfense des patients et elles travaillentavec les clients pour faire entendre la voix du patient dune manire significative et percutante , ditMme Levine.

Un grand nombre dentreprises pharmaceutiques trs avant-gardistes tablissent leur marquegrce aux relations publiques , explique Mme Levine. Carol est honore dtre intronise au CanadianHealthcare Marketing Hall of Fame, considrant cet honneur comme une reconnaissance des relationspubliques dans lindustrie du marketing des soins de sant.



Carol Levineenergi PR

Toronto and Montreal



7/12

FINDING THE MOTIVATION to head in to work or tackle thenext big project is never hard to come by in thehealth business, according to a 30-year industryveteran and head of Canadas premier vaccine man-

ufacturer. I am able to play a small part in pre-venting disease and saving lives in Canada and all

around the world, says Mark Lievonen, President of SanofiPasteur Limited in Toronto.

We make vaccines that prevent disease and save lives.Smallpox has been eradicated from the face of the Earth, andpolio could be. So every day, I come to work thinking about ourend product and how it actually impacts human lives.

We have a number of global products and R&D mandates.Our five-component acellular pertussis vaccine, which is ourwhooping cough vaccine, is the only billion-dollar biotech prod-uct developed, manufactured, and exported from Canada,Lievonen says proudly.

Lievonen started in a finance role at ConnaughtLaboratories in 1983. Institut Mrieux acquired ConnaughtBiosciences in 1989, and Lievonen became Senior VP forCommercial Development and Administration in 1990, a role he

held for roughly seven years. He was responsible for establishingthe companys Mexico affiliate as well as the cancer vaccine pro-gram, and in 1998 Lievonen was appointed acting president ofwhat was then Aventis Pasteur. He was confirmed as president the following year.

The cancer vaccine program, which began in 1997, was a particularly exciting undertak-ing, Lievonen says. Our company was very much involved with developing vaccines to preventinfectious diseases, and this was about developing vaccines for treating cancer, he says. Heand his team advocated that the project be located in Canada, and Aventis Pasteur committed$350 million in funding over 10 years, with a $60 m illion contribution from the Governmentof Canada.

Because we had put the research and development infrastructure, capabilities and plat-forms in place in Toronto, we were able to evolve and maintain the R&D footprint in Canada.Now the Toronto site is the North American Centre of Excellence for Analytical andBioprocessing R&D, says Lievonen.

Lievonen says he has sought mentors and experience broadly across diverse fields. Heholds the positions of Vice-Chair, Ontario Institute for Cancer Research; Chair, MarkhamStouffville Hospital Foundation; First Vice-Chair, Rx&D; and more, past and present. Twentyyears ago, he also spearheaded Canadas only mentored science competition, the Sanofi

BioGENEius Challenge Canada (SBCC), to foster biotechnology talent in Canada among highschool students.

He met Dr. John Evans, past president of the University of Toronto and founder of theOntario Cancer Research Network, on Sanofi Pasteurs Board of Directors. John Evans was areal mentor, and working with him on various non-profit boards was a real learning experi-ence, says Lievonen. He says other mentors have included Joe Rotman; Dr. Cal Stiller, cur-rently Chair of the Ontario Institute for Cancer Research; and Dr. Henry Friesen, the founderof the Canadian Institutes of Health Research (CIHR).

TROUVER LA MOTIVATION POUR ALLER TRAVAILLER ou soccuper duprochain grand projet nest jamais difficile faire dans ledomaine de la sant, selon un vtran de 30 ans dans lindus-trie et dirigeant chez le leader des manufacturiers de vaccins

au Canada. Je suis en mesure dapporter ma modeste con-tribution dans la prvention des maladies et de sauver des vies

au Canada et dans le monde entier , a dclar Mark Lievonen, prsident deSanofi Pasteur Limited Toronto.

Nous produisons des vaccins qui prviennent les maladies et sauventdes vies. La variole a t radique de la surface de la Terre, et la poliomylite

pourrait ltre aussi. Ce qui fait que je me rends au travail tous les jours enpensant notre produit final et de son impact sur les vies humaines.

Nous avons un certain nombre de produits globaux et des mandats derecherche et de dveloppement. Notre vaccin anticoquelucheux acellulaire

cinq composants (notre vaccin contre la coqueluche) est le seul produitbiotechnique un milliard de dollars dvelopp, produit et export auCanada, proclame firement M. Lievonen.

M. Lievonen a dbut chez Connaught Laboratories en 1983 dans le

dpartement des finances. LInstitut Mrieux a fait lacquisition de ConnaughtBiosciences en 1989, et M. Lievonen est devenu le premier vice-prsident dudveloppement commercial et de ladministration en 1990, un poste quil aoccup pendant environ sept ans. Il tait responsable de ltablissement de la

socit affilie de lentreprise au Mexique ainsi que du programme de vaccina-tion contre le cancer. En 1998, M. Lievonen a t nomm prsident par intrimde ce qui tait alors Aventis Pasteur. Il fut confirm ce poste lanne suivante.

Le programme de vaccination contre le cancer qui a dbut en 1997 tait une entreprise partic-ulirement excitante, dit M. Lievonen. Notre s ocit a t trs implique dans le dveloppement de vac-cins pour prvenir les maladies infectieuses et cela concernait le dveloppement de vaccins pour le traite-ment du cancer , indique-t-il. Son quipe et lui-mme ont prconis que le projet soit situ au Canada,

et Aventis Pasteur a investi 350 millions de dollars sur 10 ans, avec une contribution de 60 millions dedollars du gouvernement du Canada.

Ltablissement des infrastructures de recherche et de dveloppement, des capacits et d es plate-formes Toronto nous a permis dvoluer et de maintenir une prsence stratgique de la recherche et

du dveloppement au Canada. Le site de Toronto est dsormais le centre nord-amricain dexcellencepour la recherche et le dveloppement analytique et des bioprocds , explique M. Lievonen.

M. Lievonen rvle quil a cherch des mentors et de lexprience dune faon gnrale dans di versdomaines. Il a occup ou occupe prsentement, entre autres, les postes de vice-prsident de lInstitut

ontarien de recherche sur le cancer; de prsident de la Markham Stouffville Hospital Foundation; et depremier vice-prsident de recherche et dveloppement. Il y a de cela vingt ans, il a galement diriglunique concours de sciences mentor du Canada, l e Sanofi BioGENEius Challenge Canada (SBCC), afin

dencourager, chez les lves du secondaire, le talent dans la biotechnologie au Canada.Il a rencontr le Dr John Evans, ancien prsident de lUniversit de Toronto et fondateur du Rseau

ontarien de recherche sur le cancer, au conseil dadministration de Sanofi Pasteur. John Evans a t unvritable mentor; et travailler avec lui dans diffrents conseils sans but lucratif tait une vritable expri-ence dapprentissage , affirme Mark Lievonen. Il dit que, parmi dautres mentors, on comptait Joe

Rotman, le Dr Cal Stiller, actuellement prsident de lInstitut ontarien de recherche sur le cancer et le DrHenry Friesen, fondateur des Instituts de recherche en sant du Canada (IRSC).

Mark LievonenSanofi Pasteur Limited

Toronto





8/12

ACAREER IN MARINE BIOLOGY AND OCEANOGRAPHY is what JimShea, General Manager, Council for ContinuingPharmaceutical Education (CCPE) in Montreal since2009, had envisioned for his lifes work, but in the end

he opted to explore science on land rather than underwater. Shea earned a Bachelor of Science degree and a

Master of Science degree from McGill U niversity in Montreal and wasdoing field work on Baffin Island in 1988. With federal cuts to theDepartment of Fisheries and Oceans on the horizon, Jim did not seea long-term future in oceanography.

The pharmaceutical industry came onto his radar and theMontreal native and resident applied to work as a Toronto-based salesrepresentative for Merck Frosst. After six interviews in less than oneweek, Shea was hired.

I was inspired by the idea of talking to doctors about life-chang-ing medications and impacting peoples lives, says Shea.

He won several awards as a sales representative, boasting topsales for Noroxin, a drug prescribed to treat urinary tract infections.As a sales representative, Shea sought to engage in conversation withphysicians rather than list facts about the drug.

The drug was a time-saver because the duration of treatmentwas three days, says Shea. A woman was able to get back to her nor-

mal life routine more quickly.After being in the field for nearly four years, he returned to

Montreal to work out of Mercks head office, becoming a sales reptrainer.

We were talking at physicians rather than having a dialogue with them, says Shea. Itcame down to understanding the needs of the physician and challenging the physician. I want-ed the representatives to use their materials and information to make doctors think. No mat-ter what the tools involved in the interaction, and now even using an iPad, its about makingthe customer, in this case the physician, think.

Shea held other positions at Merck including Group Health Manager, Director of Sales andStrategic Planning, and Director of Field Sales Development. I saw my role as developingtraining, necessary to build the [sales] representative of the future, he says.

Sheas passion for educating representatives in the field led him to volunteer as a Directoron the Board of Directors of the CCPE. I thought the role of the CCPE was important, explainsShea, noting currently that the overwhelming majority of Canadian pharma sales representa-tives are accredited by CCPE. If we have the ability to enhance the credibility of the pharma-ceutical sales representative through education, as an industry, our reputation will be elevat-ed.

A father of three, hockey coach, and former soccer coach, Shea is enthused about CCPEsexpansion of educational opportunities for sales representatives, who can be one of the mostvaluable resources for physicians.

JIM SHEA, directeur gnral du Conseil de formation pharmaceu-tique continue (CFPC) Montral depuis 2009, se voyait fairecarrire dans la biologie marine et locanographie, mais il achoisi dexplorer la science sur la terre ferme plutt que sous

leau. M. Shea a obtenu un baccalaurat s sciences et unematrise s sciences lUniversit McGill de Montral et travail-

lait sur lle de Baffin en 1988. Alors que sannonaient des coupes budg-taires fdrales au ministre des Pches et des Ocans, Jim ne voyait pasdavenir long terme dans locanographie.

Aprs avoir dcouvert lindustrie pharmaceutique, le Montralais apostul un emploi de reprsentant commercial bas Toronto pour

Merck Frosst. Aprs six entretiens en moins dune semaine, M. Shea at embauch.

Lide de parler des mdecins de mdicaments rvolutionnaireset dinfluencer la vie des gens ma inspir , explique M. Shea.

Il a remport plusieurs prix dans sa profession et est parmi lesmeilleurs reprsentants pour Noroxin, un mdicament prescrit dans letraitement des infections urinaires. En tant que reprsentant commer-cial, M. Shea cherchait engager la conversation avec les mdecins au

lieu de leur prsenter simplement des faits propos du mdicament. Ce mdicament a permis de gagner du temps, car la dure du

traitement tait de trois jours, affirme M. Shea. Une femme a pu repren-

dre sa vie normale plus rapidement. Aprs avoir travaill sur le terrain pendant presque quatre ans, M.Shea a retrouv Montral pour travailler au sige social de Merck la for-

mation des reprsentants commerciaux. Nous faisions des discours aux mdecins au lieu davoir un vrai dialogue avec eux, indique M.

Shea. Au bout du compte, il fallait comprendre les besoins du mdecin et le remettre en question. Jevoulais que les reprsentants utilisent leurs documents et leurs informations pour encourager lesmdecins rflchir. Peu importe les outils utiliss dans la conversation, et de nos jours, mme laide

dun iPad, lobjectif est de faire rflchir le client, cest--dire le mdecin. M. Shea a occup dautres postes chez Merck, notamment celui de gestionnaire des rgimes das-

surances collectives, de directeur des ventes et de la planification stratgique et de directeur du dveloppe-ment des ventes sur le terrain. Je conois mon rle comme un perfectionnement de la formation nces-

saire pour tablir la profession de reprsentant commercial pour lavenir , affirme M. Shea.La passion de M. Shea pour la formation des reprsentants sur le terrain la pouss se porter

volontaire au poste de directeur du c onseil dadministration du CFPC. Jai pens que le rle du CFPCtait important , explique M. Shea en faisant remarquer qu lheure actuelle, la grande majorit des

reprsentants commerciaux canadiens dans le domaine pharmaceutique sont accrdits par le CFPC. Si nous avons la possibilit damliorer la crdibilit des reprsentants commerciaux pharmaceutiques

par le biais de lducation, en tant quindustrie, notre rputation nen sera que meilleure. Pre de trois enfants, entraneur de hockey et lancient entraneur de football, M. Shea est ent-

housiasm par lexpansion par le CFPC des possibilits de formation des reprsentants commerciaux,qui peuvent tre lune des ressources les plus prcieuses pour les mdecins.

Jim SheaCCPE-CFPC

Montreal





9/12

WORK IN G T O B E A FORCE for not only social and eco-nomic progress for a community half a worldaway, but also to support the living land aroundand within that community, Norman Cook,

Senior Account Manager at Rogers Publishing, iscarrying on a dream of his fathers: Lewa

Canada, the Canadian arm of the Lewa Wildlife Conservancy in Kenya.Cook is on Lewa Canadas advisory board.

The Lewa non-profit Wildlife Conservancy was established in1995, and encompasses a protected area of more than 50,000 acresin Kenya, Cook says. Since then their efforts include the distinction ofbringing the rare black rhinoceros back from the edge of e xtinction.

However, the scope of Lewa goes far beyond protecting endan-gered wildlife. Lewa is also strongly involved with helping the localcommunities of people, says Cook. The organization helps tofinance and plan education for the people, healthcare, and develop-ment of water projects that ensure clean, safe water for the people.Lewa is dedicated toward the idea that the needs of nature and theneeds of people co-exist and actually benefit each other.

His father, John A. Cook, laid the groundwork for what wouldbecome Lewa Canada before he passed away in 2003. The projectcontinued, and was established as a registered charity in Apr. 2005.Since then Lewa Canada has raised more than US$2.6 million in sup-port of the conservancy. That includes US$1.26 million for Lewasconservation and wildlife protection initiatives, more thanUS$462,000 for the Lewa Education Program, and more thanUS$525,000 for community development.

It is really about helping the people help themselves, says Cook. Naturally educationis a key way of doing that, and helping people with healthcare issues, including vaccinations,clean water supplies, contraception awareness.

Lewa provides more than 700 annual bursaries to students in primary, secondary, andtertiary education, says Cook. The charity also provides the Womens Micro-Credit program, tohelp women improve their often especially difficult circumstances and to enhance their abili-ties to move their communities forward.

And Cook is happy to sweat for Lewa Canada. In 2005 he ran the half-marathon courseof the annual Safaricom Marathon through the conservancy. Running a world-class coursethrough the breath-stealing Kenyan highlands alongside f ormer Olympians and other runnersfrom around the world, he and his sister together earned approximately $20,000 in pledges forthe charity.

It is not the easiest economy in the world to raise funds in right now, but Lewa Canadahas certainly had some very good successes, says Cook.

NORMAN CO OK SENGAGE DEVENIR un moteur non seule-ment du progrs social et conomique dune commu-naut lautre bout du monde, mais aussi dagir

lappui de la terre vivante autour de et au sein de cettecommunaut. Ce Principal charg de comptes Rogers Publishing poursuit le rve de son pre : Lewa

Canada, la branche canadienne de Lewa Wildlife Conservancy au Kenya.

Cook est un membre du conseil consultatif de Lewa Canada.Lorganisme but non lucratif, Lewa Wildlife Conservancy, a t

tabli en 1995 et comprend une aire protge de plus de 50 000 acres auKenya, dit Cook. Ds lors, leurs efforts inclut la distinction davoir sauv

le rare rhinocros noir qui tait de la voie de disparition. Pourtant, la porte du travail du Lewa Wildlife Conservancy

stend beaucoup plus loin que la protection despces en voie de dis-

parition. En plus, Lewa sengage fond aider les communauts locales ,dit Cook. Lorganisme finance et planifie lducation pour les gens, lessoins de sant, et le dveloppement damnagements hydrauliques poursassurer que les gens ont accs d e leau potable. Lewa tient lide que

les besoins de la nature et les besoins des gens coexistent et savantagentmutuellement.

Son pre John A. Cook prpar le terrain de Lewa Canada avant quil

ne steigne en 2003. Le projet a continu et sest tabli en tant quor-ganisme de bienfaisance enregistr en avril 2005. Ds lors, Lewa Canadaa collect plus de 2,6 million $ USD lappui du Lewa WildlifeConservancy. Ce montant inclut 1,26 million $ USD pour les initiatives deconservation et protection des espces naturelles de Lewa, plus de 462

000 $ USD pour le programme dducation de Lewa et plus de 525 000 $ USD pour le dveloppementcommunautaire.

Dans le fond, il s agit daider les gens saider eux-mmes , dit Cook. Naturellement, ledu-cation est un moyen principal daccomplir cela, et daider les gens avec des problmes de sant publ ique,

y compris les vaccinations, lapprovisionnement en eau potable et la sensibilisation la contraception. Lewa fournit plus de 700 bourses dtudes chaque anne aux tudia nts aux niveaux primaires, sec-

ondaires et tertiaires, dit Cook. Lorganisation caritative comprend aussi un programme de micro-crditpour les femmes, afin de les a ider amliorer leurs conditions de vie qui sont souvent particulirement

difficiles et de cultiver leurs capacits de mobiliser leurs communauts vers lavenir.Transpirer pour lorganisme Lewa Canada ne drange pas Cook. En 2005, il a couru le semi-

marathon du Marathon Safaricom annuel travers le Lewa Wildlife Conservancy. En courant un parcoursde classe mondiale travers les massifs impressionants du Kenya ct danciens athltes olympiques

et dautres coureurs venant des quatre coins du monde, Norman et sa soeur ont collect presque 20 000

$ en promesses de dons pour lorganisation caritative. Collecter des fonds dans une telle conomie nest pas vident lheure actuelle, mais Lewa

Canada a sans doute connu de grands succs , dit Cook.

C. Norman CookRogers Publishing

Toronto

Phil Diamond Award for

Community Service





10/12

Inductees MembresDoug Ballingall AstraZeneca Mississauga Ontario

Angelo Botter Abbott Labs Montreal Quebec

Phil Diamond Diamond Strategic Advertising Toronto Ontario

Clifford K. Goodman Keith Health Care Mississauga Ontario

J.R. Marcotte Berlex St-Laurent Quebec

Percy Skuy Janssen-Ortho Don Mills Ontario

Sylvia Vogel Canderm Pharmacal St-Laurent Quebec

Ted Wise Pharmascience Montreal Quebec

Jimmy Ghadiali Aventis Pharma Laval Quebec

Mary Layton Media Director Toronto Ontario

Sandi Leckie Chronicle Companies Toronto Ontario

Paul Lucas Glaxosmithkline Toronto Ontario

Richard J. MacKay Stiefel Canada Montreal Quebec

Gerry McDole AstraZeneca Mississauga Ontario

Claude Perron Shire Biochem Laval Quebec

Christine Whatley Janssen-Ortho Don Mills Ontario

Donna Day Solvay Pharma Markham Ontario

Rudy Fernandes Global Health Strategy Mississauga Ontario

Sheila Gittelman Sudler & Hennessey Canada Montreal Quebec

Jean-Michel Halfon Pfizer Canada Kirkland Quebec

Gilles Lachance Council for Continuing Pharmaceutical Education Saint-Laurent Quebec

Robert Lavoie Dermtek Pharmaceuticals Dorval Quebec

David Rimell Medifacts Ottawa Ontario

John Stewart Purdue Pharma Pickering Ontario

Roy Chernoff Troutbeck Chernoff Toronto Ontario

Janet Chlebo Janssen-Ortho Don mills Ontario

Michael Cloutier AstraZeneca Mississauga Ontario

Rob Hamilton Biogen Idec Mississauga Ontario

Andr Marcheterre Merck Frosst Kirkland Quebec

Manon Richer Rogers Media Montreal Quebec

Sheila Rivest Integrated Healthcare Communications Toronto Ontario

John Suk Altana Pharma Oakville Ontario

Cialis Team Eli Lilly Canada Toronto Ontario

Lipitor Team Pfizer Canada Kirkland Quebec

Philip Blake Bayer Toronto Ontario

Susanne Cookson Boehringer Ingelheim Inc. Burlington Ontario

Daryl Erickson Medical Communications Group Montreal Quebec

Terry Johnson Allard Johnson Toronto Ontario

Joseph Knott Pangaea Group of Companies Toronto Ontario

Liette Landry Schering Canada Pointe Claire Quebec

Pierre Montanaro Pharmascience Montreal Quebec

Jacqueline Shan CV Technologies Edmonton Alberta

BOTOX Cosmetic Team Allergan Markham Ontario

Gardasil Team Merck Frosst Canada Kirkland Quebec



11/12

Inductees MembresCheryl Cann-Critchlow Boehringer Ingelheim Inc. Burlington Ontario

Lorena Di Carlo Lundbeck Canada Montreal Quebec

Neil K. Hutton Canadian Anesthesiologists Society Toronto Ontario

Graham Jobson Solvay Pharma Inc. Markham Ontario

Ronnie Miller Roche Canada Mississauga Ontario

Isabelle Mongeau Pfizer Canada Montreal Quebec

Brenda Pratscher Ogilvy Montreal Montreal QuebecKen Stallman Cundari Health Toronto Ontario

Paladin Labs Montreal Quebec

Diabetes Team Novo Nordisk Mississauga Ontario

Phil Diamond Award for community serviceCarlo Viola STA Communications Montreal Quebec

Deborah Brown EMD Serono Canada Inc. Mississauga Ontario

Ray Chepesiuk Pharmaceutical Advertising Advisory Board Pickering Ontario

Laurie Dotto Abbott Laboratories Canada Montreal Quebec

Gerard Gregory Boehringer Ingelheim Inc. Burlington Ontario

Sharon Henderson Stiefel Canada Montreal Quebec

Mike Kirkley MarketForce Cambridge Ontario

Dean Michelin Valeo Pharma Kirkland Quebec

Valeant Canada Montreal Quebec

AstraZeneca Mississauga Ontario

Phil Diamond Award for community serviceSteve Gregory IsaiX Technologies Montreal quebec

Greg Anderson Janssen-Ortho Inc. Toronto Ontario

Theresa Firestone Pfizer Canada Kirkland QuebecJunne Hinkley-Page McNeil Toronto Ontario

Dr. Andr Lalonde Society of Obstetricians and Gynaecologists of Canada Ottawa Ontario

Vince Lamanna Novo Nordisk Canada Inc. Mississauga Ontario

Michael Tremblay Astellas Pharma Canada, Inc. Markham Ontario

Vivianne Vinet CME Solutions Montreal Quebec

Phil Diamond Award for community serviceMario Daigle Allard Johnson Montreal Quebec

Lorenzo Biondi Hoffmann-La Roche Limited Canada Mississauga Ontario

James Cran Antibody Healthcare Communications Toronto Ontario

Steve Green Novo Nordisk Canada Inc. Mississauga Ontario

Regina Kulikowski Regina K Toronto Ontario

Dan Lger Lundbeck Canada Montreal Quebec

Dr. Stuart Maddin Vancouver British Columbia

Lorne Markowitz Valeant Canada Ltd. Montreal Quebec

Phil Diamond Award for community serviceMorris Goodman Pharmascience Inc. Montreal Quebec

Wendy Adams Galderma Canada Markham Ontario

Peggy Ahearn Canadian Association of Wound Care Toronto OntarioRichard Fajzel Pfizer Canada Montreal Quebec

Dominique Gilbert Lundbeck Canada Inc. Montreal Quebec

Dr. Richard M. Gladstone Association of community neurologists Toronto Ontario

Doug Grant Bayer Inc. Toronto Ontario

Barbara Reynolds Astellas Pharma Canada Inc. Markham Ontario

Phil Diamond Award for community serviceAaron and Mandy Maresky Aarons Apple Toronto Ontario



12/12

ASpecial Supplement toThe Chronicle of Healthcare Marketing

Un supplment spcial de la publicationThe Chronicle of Healthcare Marketing

April, 2013 Avril 2013

2013 Corporate Builders

Associ principals de corporation 2013

2013 Corporate Patrons

Associs de soutien de corporation 2013


bios - canadian healthcare marketing hall of fame 2013

Documents